These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 18212106)

  • 1. Failure of deferasirox, an iron chelator agent, combined with antifungals in a case of severe zygomycosis.
    Soummer A; Mathonnet A; Scatton O; Massault PP; Paugam A; Lemiale V; Mira JP; Dannaoui E; Cariou A; Lortholary O
    Antimicrob Agents Chemother; 2008 Apr; 52(4):1585-6. PubMed ID: 18212106
    [No Abstract]   [Full Text] [Related]  

  • 2. Deferasirox (Exjade): a new iron chelator.
    Med Lett Drugs Ther; 2006 Apr; 48(1233):35-6. PubMed ID: 16625144
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload.
    Cappellini MD; Taher A
    Expert Opin Pharmacother; 2008 Sep; 9(13):2391-402. PubMed ID: 18710363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deferasirox in thalassemia patients with end-stage renal disease.
    Beydoun HG; Saliba AN; Taher AT
    Am J Hematol; 2016 Oct; 91(10):E456-7. PubMed ID: 27342388
    [No Abstract]   [Full Text] [Related]  

  • 5. The oral chelator deferasirox--a new perspective for patients with iron overload.
    Fischer R
    Haematologica; 2006 Jul; 91(7):865A. PubMed ID: 16818263
    [No Abstract]   [Full Text] [Related]  

  • 6. Deferasirox--an oral agent for chronic iron overload.
    Vanorden HE; Hagemann TM
    Ann Pharmacother; 2006 Jun; 40(6):1110-7. PubMed ID: 16735647
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.
    Cappellini MD; Cohen A; Piga A; Bejaoui M; Perrotta S; Agaoglu L; Aydinok Y; Kattamis A; Kilinc Y; Porter J; Capra M; Galanello R; Fattoum S; Drelichman G; Magnano C; Verissimo M; Athanassiou-Metaxa M; Giardina P; Kourakli-Symeonidis A; Janka-Schaub G; Coates T; Vermylen C; Olivieri N; Thuret I; Opitz H; Ressayre-Djaffer C; Marks P; Alberti D
    Blood; 2006 May; 107(9):3455-62. PubMed ID: 16352812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deferasirox and children: From clinical trials to the real world.
    Origa R; Zappu A; Foschini ML; Leoni G; Morittu M; Moi P; Corpino M; Dessì C
    Am J Hematol; 2016 Jun; 91(6):E304-5. PubMed ID: 26950047
    [No Abstract]   [Full Text] [Related]  

  • 9. Deferasirox for managing iron overload in people with thalassaemia.
    Bollig C; Schell LK; Rücker G; Allert R; Motschall E; Niemeyer CM; Bassler D; Meerpohl JJ
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD007476. PubMed ID: 28809446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deferasirox (ICL670A) effectively inhibits oesophageal cancer growth in vitro and in vivo.
    Ford SJ; Obeidy P; Lovejoy DB; Bedford M; Nichols L; Chadwick C; Tucker O; Lui GY; Kalinowski DS; Jansson PJ; Iqbal TH; Alderson D; Richardson DR; Tselepis C
    Br J Pharmacol; 2013 Mar; 168(6):1316-28. PubMed ID: 23126308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral iron chelation and the treatment of iron overload in a pediatric hematology center.
    Raphael JL; Bernhardt MB; Mahoney DH; Mueller BU
    Pediatr Blood Cancer; 2009 May; 52(5):616-20. PubMed ID: 19148949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined antifungal therapy, iron chelation and surgical resection as treatment of hepatic zygomycosis in a patient with haematological malignancy.
    Busca A; Marmont F; Locatelli F; Limerutti G; Sorrentino MT; Barbui A; Patrono D; Salizzoni M; David E; De Rosa F
    Mycoses; 2010 May; 53(3):275-8. PubMed ID: 19302458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M; Carrara P; Pinto V; Forni GL
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract]   [Full Text] [Related]  

  • 14. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.
    Kontoghiorghes GJ
    Expert Opin Drug Saf; 2010 Jul; 9(4):633-41. PubMed ID: 20553089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.
    Cappellini MD; Bejaoui M; Agaoglu L; Canatan D; Capra M; Cohen A; Drelichman G; Economou M; Fattoum S; Kattamis A; Kilinc Y; Perrotta S; Piga A; Porter JB; Griffel L; Dong V; Clark J; Aydinok Y
    Blood; 2011 Jul; 118(4):884-93. PubMed ID: 21628399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea.
    Vichinsky E; Torres M; Minniti CP; Barrette S; Habr D; Zhang Y; Files B;
    Am J Hematol; 2013 Dec; 88(12):1068-73. PubMed ID: 23946212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deferasirox in mucormycosis: hopefully, not defeated.
    Soman R; Gupta N; Shetty A; Rodrigues C
    J Antimicrob Chemother; 2012 Mar; 67(3):783-4. PubMed ID: 22167245
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-term efficacy and safety of deferasirox.
    Cappellini MD
    Blood Rev; 2008 Dec; 22 Suppl 2():S35-41. PubMed ID: 19059055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective.
    Delea TE; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Pharmacoeconomics; 2007; 25(4):329-42. PubMed ID: 17402805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Transfusional independence in a patient with refractory anemia with excess blasts-2 refractory to 5-azacitidine treated with deferasirox and colony stimulating factors].
    Moreno de Gusmão B; Guinea de Castro JM; Perez-Persona E; Oiartzabal I
    Med Clin (Barc); 2014 Jan; 142(2):91-2. PubMed ID: 23790532
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.